Clinical trials: Immunity to COVID-19
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to…
- Trial name
- NCT06374394
- Testing
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike…
- Trial name
- NCT04758962
- Testing
- 1 µg CoV2 SAM (LNP)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19 Vaccination
RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a…
- Trial name
- MACH19 (NCT04951336)
- Testing
- FoTv
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronavirus, Coronavirus Infection
BCG Vaccine for Health Care Workers as Defense Against COVID 19
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW).
- Conditions
- Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
- Trial name
- BADAS (NCT04348370)
- Testing
- BCG Vaccine
- Where
- 6 sites in United States
- Volunteers
- 659 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Healthy Volunteer
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Background: Vaccines help prevent disease by causing the body to have an immune response. Many parts of this response happen in the blood. This response happens over days and weeks after getting the vaccine.
- Trial name
- NCT04025580
- Testing
- Flucelvax, Fluvirin, Fluzone High Dose
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Non-specific Effects of Vaccines
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Background: The virus SARS-CoV-2 has spread rapidly throughout the world. Seniors are at high risk of severe COVID-19 when infected.
- Conditions
- Covid19, Non-specific Effects of Vaccines, Heterologous Immunity, Morbidity
- Trial name
- NCT04542330
- Testing
- BCG-Denmark, Saline
- Where
- Denmark
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
COVID-19
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults…
- Trial name
- NCT05972993
- Testing
- mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg
- Where
- 4 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19, Coronavirus
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.
- Conditions
- COVID-19, Coronavirus, SARS-CoV-2
- Trial name
- PassItOn (NCT04362176)
- Testing
- pathogen reduced SARS-CoV-2 convalescent plasma
- Where
- 26 sites in United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University Medical Center
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD